Compare USA Rare Earth Inc. Class A Common Stock (USAR) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
USA Rare Earth Inc. Class A Common Stock vs DENTSPLY SIRONA Inc — how do they compare? USA Rare Earth Inc. Class A Common Stock trades at $10.15 (market cap $4.23B), while DENTSPLY SIRONA Inc trades at $8.54 (market cap $1.70B). The key difference: USA Rare Earth Inc. Class A Common Stock is far larger — about 2.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while USA Rare Earth Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold USA Rare Earth Inc. Class A Common Stock for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| USAR | XRAY | |
|---|---|---|
Market Cap | $4.23B | $1.70B |
Volume | 13,677,660 | 3,939,845 |
Sector | Basic Materials | Health |
52-Week High | $33.68 | $14.68 |
52-Week Low | $10.32 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $2.70B | $3.77B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
XRAY trades at $8.44, down 1.06% on the day and near its 52-week low, reflecting persistent bearish technical signals. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue, though Q2 2026 earnings beat expectations. Debt-to-asset ratio has risen to 42.88% in 2025, indicating increased financial leverage amid ongoing restructuring efforts.
The outlook remains challenging with weak profitability and high debt, but analyst consensus suggests potential upside to a $13.00 price target. Key risks include margin pressure, competitive threats, and execution of the turnaround plan. Investment appeal hinges on successful operational improvements and sustained earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
